Studies have shown that rare coding mutations contribute to BP variation, 10,11 but a recent study involving targeted sequencing of 6 BP genes identified by GWAS did not reveal novel rare Background-Rare genetic variants influence blood pressure (BP). Methods and Results-Whole-exome sequencing was performed on DNA samples from 17 956 individuals of European ancestry and African ancestry (14 497, first-stage discovery and 3459, second-stage discovery) to examine the effect of rare variants on hypertension and 4 BP traits: systolic BP, diastolic BP, pulse pressure, and mean arterial pressure. Tests of ≈170 000 common variants (minor allele frequency, ≥1%; statistical significance, P≤2.9×10 -7 ) and gene-based tests of rare variants (minor allele frequency, <1%; ≈17 000 genes; statistical significance, P≤1.5×10 -6 ) were evaluated for each trait and ancestry, followed by multiethnic meta-analyses. In the first-stage discovery, rare coding variants (splicing, stop-gain, stop-loss, nonsynonymous variants, or indels) in CLCN6 were associated with lower diastolic BP (cumulative minor allele frequency, 1.3%; β=−3.20; P=4.1×10 -6 ) and were independent of a nearby common variant (rs17367504) previously associated with BP. CLCN6 rare variants were also associated with lower systolic BP (β=−4.11; P=2.8×10 -4 ), mean arterial pressure (β=−3.50; P=8.9×10 -6 ), and reduced hypertension risk (odds ratio, 0.72; P=0.017). Meta-analysis of the 2-stage discovery samples showed that CLCN6 was associated with lower diastolic BP at exome-wide significance (cumulative minor allele frequency, 1.1%; β=−3.30; P=5.0×10 -7 ). Conclusions-These findings implicate the effect of rare coding variants in CLCN6 in BP variation and offer new insights into BP regulation. (Circ Cardiovasc Genet. 2016;9:64-70.
B lood pressure (BP) is a heritable quantitative trait influenced by both genetic and environmental stimuli. 1, 2 Persistently elevated BP is a risk factor of cardiovascular disease and a major contributor to cardiovascular death. 3, 4 Identifying genetic determinants of BP regulation may add novel insights into cardiovascular disease prevention and may lead to more efficacious treatments. Large-scale genome-wide association studies (GWAS) have reported common variants at ≈60 loci that are associated with systolic BP (SBP) and diastolic BP (DBP) in individuals of European ancestry (EA), with effect sizes ranging from 0.4 to 1.2 mm Hg for SBP and 0.2 to 0.7 mm Hg for DBP per copy of the minor allele. [5] [6] [7] Additional variants for pulse pressure (PP) and mean arterial pressure (MAP) have also been identified with effect sizes of similar magnitudes. 8 A recent large BP GWAS demonstrated that BP variants identified in EAs may have effects in individuals of African ancestry; so, an analysis of multiethnic samples has the potential to find novel genetic determinants of BP traits in this field. 9 Despite the fact that numerous BP variants have been identified by GWAS, the proportion of explained variance in BP measures remains limited. variants associated with the trait. 12 In contrast, whole-exome sequencing (WES), which captures both common and rare coding variations, has successfully been applied to identify rare coding variants contributing to multiple complex traits. 13, 14 To date, no WES study has evaluated the association between rare coding variants and BP traits. To address this, we performed first-stage WES on 9950 EAs and 4547 black individuals from 6 large population-based cohort studies to examine the effect of rare coding variants on SBP, DBP, PP, MAP, and hypertension. The second-stage WES was conducted in 2 EA cohorts, comprising 3459 individuals.
Methods

Study Populations and BP Measurements
The first-stage discovery sample consisted of 10 403 individuals from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium 15 [16] [17] [18] [19] [20] [21] [22] [23] [24] For all cohorts in this study, BP values were measured at the first examination and antihypertensive medication use was recorded from the medication history or medication inventory at the same time. Detailed descriptions for BP measurements in each cohort are summarized in Methods section in the Data Supplement. For individuals taking antihypertensive medication, untreated BP values were imputed by adding 15 mm Hg to measured SBP and 10 mm Hg to measured DBP. 25, 26 All participants provided written informed consent as approved by local institutional review committees.
Exome Sequencing and Variant Calling
For CHARGE, DNA samples were prepared using the Baylor College of Medicine Human Genome Sequencing Center VCRome 2.1 design 27 (42Mb; NimbleGen) and were sequenced and called together. For ESP, DNA samples were prepared using either Roche Nimblegen SeqCap EZ or Agilent SureSelect Human All Exon 50Mb. All samples were paired end sequenced using Illumina GAII or HiSeq instruments. Details on sequencing, variant calling, and variant quality control are provided in Methods section in the Data Supplement.
Annotation of Whole-Exome Sequence Variants
To facilitate meta-analysis between CHARGE and ESP, a combined variant annotation file was created to include all quality variants observed in either CHARGE or ESP. Variants were annotated from CHARGE and ESP separately using ANNOVAR 28 and dbNSFP version 2.0 29 according to the reference genome GRCh37 and National Center for Biotechnology Information RefSeq. Coding variants were annotated to a unique gene, as well as the following categories that were considered for inclusion in gene-based tests: splicing, stop-gain, stop-loss, nonsynonymous variants, and indels. The CHARGE and ESP annotated variant lists were merged into a joint file to ensure that a variant present in both studies had the same reference allele and annotation category.
Statistical Analyses
Individuals with untreated SBP <60 mm Hg or untreated DBP <40 mm Hg were excluded from analysis. PP was calculated by subtracting DBP from SBP, and MAP was defined as DBP plus PP/3. Hypertension was defined as individuals having SBP ≥140 mm Hg or DBP ≥90 mm Hg or use of BP-lowering medication at the first examination. All 4 continuous traits were winsorized at the 99.9th percentile before the analysis by using BP data available from the entire cohort. Cohort-level and ancestry-specific analyses were carried out using the R seqMeta package (http://cran.r-project.org/web/packages/ seqMeta/index.html) adjusting for age, age-squared, sex, body mass index, and principal components (generated by EIGENSTRAT 30 ) or study site as needed within each cohort and ancestry stratum. Fixedeffect inverse variance-weighted meta-analyses of single-variant and gene-based tests were then conducted using seqMeta to combine cohort-level and ancestry-specific summary results for multiethnic analyses. Only variants on autosomal chromosomes were analyzed in this study, and all analyses used additive genetic models.
Single variants (common variants; minor allele frequency [MAF], ≥1%) were tested for association with the 4 BP traits and hypertension. Single-variant associations were considered to be significant if P≤2.9×10 -7 , reflecting Bonferroni correction for testing ≈170 000 variants. For gene-based analysis, we performed a T1 test for each gene, in which annotated coding variants with MAF ≤1% within a gene were collapsed into a single-gene-based burden score, and then, the score was analyzed using linear regression. 31 We also implemented the Sequence Kernel Association Test using default β weights, 32 which analyzed annotated coding variants with an MAF of ≤1% and is more powerful when effects are both BP raising and BP lowering. For multiethnic meta-analyses, genes with cumulative MAF (cMAF) ≥0.1% were analyzed using both T1 test and Sequence Kernel Association Test implemented by seqMeta, and an association was considered to be significant if P≤1.5×10 -6 given a Bonferroni correction for ≈17 000 genes and 2 burden tests.
Second-Stage Discovery
The top T1 gene-based association identified in this study was followed up in 2 independent sample sets, RS (n=2205 EAs) and ERF (n=1254 EAs). For ERF, sequencing was done using the Agilent version V4 capture kit on an Illumina Hiseq2000 sequencer. In the RS, individuals were sequenced using the Nimblegen SeqCap EZ V2 capture kit on an Illumina Hiseq2000 sequencer. Details on sequencing, variant calling, and variant quality control are provided in Methods section in the Data Supplement. Coding variants included in the analyses were defined as splicing, stop-gain, stop-loss, nonsynonymous, and indels. A gene-based T1 test was conducted as described above, with the significance threshold set at P<0.05.
Results
Participant Characteristics
The study sample for this analysis consisted of 17 956 individuals, with 14 497 in the first-stage discovery data set and 3459 in the second-stage discovery data set. In general, individuals from each cohort were middle aged, with a greater proportion of women than men. Compared with EAs, blacks had higher prevalence of hypertension, type 2 diabetes mellitus, and higher mean body mass index and BP values. Ancestrystratified characteristics of the 2-stage discovery cohorts are summarized in Table I in the Data Supplement.
Gene-Based Test Results
For each BP trait, the first-stage discovery results from T1 and Sequence Kernel Association Test gene-based tests at P<5×10 -4 and rare coding variants in the identified genes are summarized in Tables II and III in the Data Supplement. The most significant association was for the chloride channel, voltage-sensitive 6 gene (CLCN6) with DBP, in the T1 test. There were 95 rare coding variants in CLCN6 present in CHARGE or ESP (cMAF, 1.3%; annotated variant level results with DBP are shown in Table IV in the Data Supplement); 34 of which were not reported by the Exome Aggregation Consortium (http://exac.broadinstitute.org, Accessed March 31, 2015) . The aggregation of rare coding variants in CLCN6 was associated with lower DBP (β=−3.20; P=4.1×10 -6 ), SBP (β=−4.11; P=2.8×10 -4 ), and MAP (β=−3.50, P=8.9×10 -6 ) but was not associated with PP. Rare coding variants were seen in both ancestries with similar cMAF of 1.2% (Figure 1 ). The magnitude of the effect sizes was consistent between EA and blacks, where each copy of a rare allele was associated with 3 to 4 mm Hg lower DBP (Table 1 ). There were 29 BP genetic loci, including 42 genes, previously reported by Ehret et al, 6 the largest BP GWAS thus far. Tables V and VI in the Data Supplement contain T1 and Sequence Kernel Association Test results for the 42 genes and the 4 BP traits. After accounting for multiple testing for the 42 genes (P<0.001), only CLCN6 exceeded this significance threshold.
In a T1 burden test for hypertension in the first-stage discovery sample, rare coding variants in CLCN6 accounted for a 28% lower odds of hypertension (odds ratio, 0.72; 95% confidence interval, 0.55-0.94; P=0.017). CLCN6 is located in 1p36. A common intronic single-nucleotide polymorphism (SNP), rs17367504 (MAF, 14%), 3.4 kb upstream from CLCN6, was associated with reduced DBP in a previous GWAS. 5 Therefore, we re-examined the association between CLCN6 and DBP in CHARGE EAs and blacks, adjusting for rs17367504. The results showed the observed effect size, and significance of CLCN6 on DBP levels had the same magnitude as in the unconditional analyses ( Table 2 ).
Corroborating Evidence
There are 3 sources of corroborating data for the observed first-stage discovery findings: second-stage discovery, previous GWAS, and animal model studies. When compared with the first-stage discovery cohorts, the 2-EA second-stage cohorts had a smaller cMAF (cMAF, 0.3% versus 1.3%) for CLCN6 in the T1 test, but the direction of the effect was consistent. CLCN6 remained significantly associated with DBP in ERF (β=−7.25; P=0.04) but not in RS (β=−1.19; P=0.68; variant level results are shown in Table VII in the Data Supplement; T1 results for the other BP traits are shown in Table VIII in the Data Supplement). After meta-analyzing the 2-stage discovery samples, CLCN6 was exome wide significantly related to lower DBP (cMAF, 1.1%; β=−3.30; P=5.0×10 -7 ; Figure 2 ). Second, CLCN6 is near a previous DBP GWAS locus 5 that contains multiple candidate genes. Third, a knockout homologue Clcn6 in the rat results in reduced BP levels and lower hypertension risk, 33 supporting results similar to our observations.
Single-Variant Test Results
Common variants (MAF≥1%) were analyzed in relation to BP traits using multiethnic meta-analyses. No single-variant test reached our predefined significance threshold. The associations for each BP trait with P<5×10 -5 are shown in Table IX in the Data Supplement. Four coding variants located in ULK4, SLC39A8, HFE, and SH2B3 previously reported by Ehret et al, 6 the largest BP GWAS thus far, were captured in this study, and thus, were available for analysis. Our results showed consistent directional effects for the coded alleles with the GWAS findings, and the associations with DBP all had P<0.05 (Table X in the Data Supplement).
Discussion
By analyzing exome sequence data from 2 large consortia (n=14 497) in relation to BP traits, we identified an aggregation of rare coding variants in CLCN6 that were associated with lower DBP among EAs and blacks. The association was corroborated in the second-stage discovery cohorts, and a meta-analysis of 2-stage discovery cohorts showed that CLCN6 was exome wide significantly related to lower DBP (P=5.0×10 -7 ) . In addition to DBP, CLCN6 was related to lower levels of SBP and MAP, as well as lower risk of hypertension. This indicates a potential role of CLCN6 in BP regulation and positions this gene as an attractive therapeutic target for future studies.
We demonstrated that the effect of CLCN6 was independent of a previously reported common GWAS SNP in this region. CLCN6 is located in 1p36, a region with several BP candidate genes identified by GWAS, including AGTRAP, Figure 1 . Chloride channel, voltage-sensitive 6 (CLCN6) rare coding mutations discovered in the first-stage cohorts. Blue dots above and red dots below represent the mutations observed in European ancestry or blacks, respectively. Yellow lines across the gene connect the same mutation seen in both ancestries.
MTHFR, CLCN6, NPPA, and NPPB. A common SNP in this region is rs17367504, in the intron of MTHFR, with a modest BP effect size (<1 mm Hg) in BP. 6, 34 We identified 95 rare coding variants in CLCN6, and these rare variants, in aggregate, were associated with decreased BP levels (3-4 mm Hg), independent of the tagging SNP, rs17367504. The effect size for the rare coding variants in CLCN6 was about 4-to 6-fold larger than previous common BP variants from GWAS.
CLCN6 belongs to the voltage-dependent chloride channel (ClC) family. The function of chloride channels ranges from ion homeostasis to cell migration and regulation of electric excitability. 35 However, the physiological role of CLCN6 is less well characterized. CLCN6 has 4 conserved domains, where ClC_6_like and CBS_pair_EriC_assoc_euk_bac are the most likely functional domains. Most rare variants identified in our study (80%) are located in these 2 domains. ClC_6_like belongs to the ClC superfamily. It shares the unique double-barreled architecture and voltage-dependent gating mechanism, although the function is not clear. 35 CBS_ pair_EriC_assoc_euk_bac, coexisting with other functional domains, contains 2 tandem repeats of the cystathionine β-synthase (CBS pair) domains, and mutations within this domain are associated with Bartter syndrome. 36 Interestingly, CLCNKA and CLCNKB, 2 other genes belonging to chloride channel family, share CBS_pair_EriC_assoc_euk_bac domain and are involved in BP regulation. CLCNKA and CLCNKB play a key role in transporting chloride ions through ClC Ka and Kb, which is part of the mechanism of kidney reabsorption of sodium chloride to help maintain BP. 37 Studies have shown CLCNKA and CLCNKB harbored mutations associated with low BP in Mendelian conditions, including Bartter and Gitelman syndromes. 38 Rare independent mutations in other renal salt handling genes, including SLC12A3, SLC12A1, and KCNJ1, were reported to contribute to lower BP levels (eg, −3.4 mm Hg for long-term average DBP) and reduced the prevalence of hypertension in a community-based study as well. 11 Our study showed that CLCN6 has a similar magnitude of effect on BP levels and hypertension. Consistent results were observed in both EAs and AAs (β=−3.12 for EAs and β = −3.44 for AAs), which would enhance the global understanding of genetic determinants for BP regulation.
Common variants associated with BP have been studied extensively in large-scale GWAS, and many variants have been reported with effects of ≈0.5 to 1 mm Hg (per variant allele). 5, 6, 8, 9, [39] [40] [41] In this study, in contrast with the rare variant result, we did not identify novel common variants that significantly influenced BP levels. We showed consistent results for 4 common BP SNPs, located in ULK4, SLC39A8, HFE, and SH2B3, that were reported by the International Consortium for Blood Pressure 6 and were captured in our WES. Largescale GWAS is a powerful approach to detect common variants associated with complex traits 42 ; we had limited power to detect novel common variants in this study given the sample size with whole exome sequence compared with GWAS.
To our knowledge, this study is the first and largest WES study for BP traits among EAs and blacks. We observed rare coding variants in CLCN6 that in aggregate have large effects on BP. Additional sequencing in larger samples will help demonstrate the robustness of our findings, and further replication is warranted. Our study focused on BP measurements at baseline, and repeat measurements may provide a more precisely estimated phenotype to detect genetic determinants for BP variation. 43 Therefore, future WES studies incorporating repeated BP measurements are justified. In summary, by analyzing WES, we identified that an aggregation of rare coding variants in CLCN6 was associated with lower DBP and lower risk of hypertension among 13 409 EAs and 4547 blacks from 8 large population-based cohort studies. In addition, the effect sizes of CLCN6 were consistent across two ancestries. Our findings provide evidence for a functional role of CLCN6 in BP regulation and point toward this gene as a therapeutic target.
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